Trop2 Expression in Extramammary Paget’s Disease and Normal Skin
Autor: | Takamichi Ito, Yuka Tanaka, Maho Murata, Keiko Tanegashima, Yumiko Kaku-Ito, Yoshinao Oda, Hiroki Hashimoto |
---|---|
Jazyk: | angličtina |
Rok vydání: | 2021 |
Předmět: |
0301 basic medicine
Keratinocytes Male Pathology Immunoconjugates Skin Neoplasms medicine.medical_treatment Gene Expression Targeted therapy sacituzumab govitecan 0302 clinical medicine Biology (General) Spectroscopy Skin Aged 80 and over Membrane Glycoproteins Apocrine trophoblast cell surface antigen 2 (Trop2) General Medicine Middle Aged targeted therapy Computer Science Applications Chemistry medicine.anatomical_structure Apocrine Glands Paget Disease Extramammary 030220 oncology & carcinogenesis Sacituzumab govitecan Female Hair Follicle Adult medicine.medical_specialty QH301-705.5 Antibodies Monoclonal Humanized Extramammary Paget's disease Catalysis Article Inorganic Chemistry Infundibulum 03 medical and health sciences Sebaceous Glands Antigen Antigens Neoplasm medicine Biomarkers Tumor Humans Physical and Theoretical Chemistry QD1-999 Molecular Biology Aged business.industry Organic Chemistry medicine.disease Epithelium 030104 developmental biology Gene Expression Regulation Camptothecin Skin cancer business extramammary Paget’s disease Cell Adhesion Molecules |
Zdroj: | International Journal of Molecular Sciences Volume 22 Issue 14 International Journal of Molecular Sciences, Vol 22, Iss 7706, p 7706 (2021) |
ISSN: | 1422-0067 |
Popis: | Extramammary Paget’s disease (EMPD) is a rare skin cancer arising in the apocrine gland-rich areas. Most EMPD tumors are dormant, but metastatic lesions are associated with poor outcomes owing to the lack of effective systemic therapies. Trophoblast cell surface antigen 2 (Trop2), a surface glycoprotein, has drawn attention as a potential therapeutic target for solid tumors. Sacituzumab govitecan, an antibody–drug conjugate of Trop2, has recently entered clinical use for the treatment of various solid cancers. However, little is known about the role of Trop2 in EMPD. In this study, we immunohistochemically examined Trop2 expression in 116 EMPD tissue samples and 10 normal skin tissues. In normal skin, Trop2 was expressed in the epidermal keratinocytes, inner root sheaths, and infundibulum/isthmus epithelium of hair follicles, eccrine/apocrine glands, and sebaceous glands. Most EMPD tissues exhibited homogeneous and strong Trop2 expression, and high Trop2 expression was significantly associated with worse disease-free survival (p = 0.0343). These results suggest the potential use of Trop2-targeted therapy for EMPD and improve our understanding of the skin-related adverse effects of current Trop2-targeted therapies such as sacituzumab govitecan. |
Databáze: | OpenAIRE |
Externí odkaz: |